Also trades as: AVH.AX (ASX) · $vol 1M
AVHHL OTC
AVITA Medical, Inc.
1W: -2.0%
1M: +4.3%
3M: +122.7%
YTD: +174.9%
1Y: +56.8%
3Y: -21.6%
5Y: -2.5%
$1.96
-0.04 (-2.00%)
Overview
News
Chart
Smart Money
Financials
Income Statement
Cash Flow
Balance Sheet
Earnings
Dividends
Analysis
Technicals
Weather
Peers
ESG
Institutions
Dark Pool
Short Interest
Supply Chain
Supply Chain Overview
5 relationships5
As Filer
counterparties named
0
As Counterparty
mentioned by others
2
Rel. Types
2024-01-10
Earliest Filing
2025-08-07
Latest Filing
partner: 3
investor: 2
Counterparties (Filed by AVHHL)
5 relationshipsCompanies named in AVHHL's SEC 8-K filings as business counterparties.
| Counterparty | Ticker | Relationship | Summary | Filing Date | SEC |
|---|---|---|---|---|---|
| K&L Gates LLP | — | investor | Counsel to the Borrower providing legal opinion on the share issuance. | 2025-08-07 | View |
| Stedical Scientific, Inc. | — | partner | Partnered with AVITA Medical for manufacturing and distribution of PermeaDerm biosynthetic wound matrix. | 2025-03-17 | View |
| Collagen Matrix, Inc. dba Regenity Biosciences | — | partner | Exclusive development and distribution partner for a collagen-based dermal matrix | 2024-07-31 | View |
| Linden Capital Partners | LIN | investor | Portfolio company owner of Regenity Biosciences | 2024-07-31 | View |
| Stedical Scientific, Inc. | — | partner | Exclusive multi-year distribution agreement to commercialize PermeaDerm® Biosynthetic Wound Matrix in the United States. | 2024-01-10 | View |
Recent 8-K Filings (20)
| Filing Date | Description | Type | SEC |
|---|---|---|---|
| 2026-08-11 | Material Agreement; Exhibits | Agreement | View |
| 2026-08-06 | Shareholder Vote | View | |
| 2026-06-08 | Material Agreement; Exhibits | Agreement | View |
| 2026-06-04 | Officer/Director Change; Shareholder Vote | View | |
| 2026-05-01 | Officer/Director Change; Regulation FD; Exhibits | View | |
| 2026-02-12 | Results of Operations and Financial Condition; Financial Statements and Exhibits | View | |
| 2026-01-13 | Entry into Material Definitive Agreement; Termination of Material Definitive Agreement; Results of O | Agreement | View |
| 2026-01-05 | Departure/Election of Directors; Appointment of Officers; Financial Statements and Exhibits | View | |
| 2025-11-06 | Entry into Material Definitive Agreement; Results of Operations and Financial Condition; Financial S | Agreement | View |
| 2025-10-17 | Departure/Election of Directors; Appointment of Officers; Regulation FD Disclosure; Financial Statem | View | |
| 2025-08-18 | Unregistered Sales of Equity Securities | View | |
| 2025-08-12 | Other Events; Financial Statements and Exhibits | View | |
| 2025-08-07 | Entry into Material Definitive Agreement; Results of Operations and Financial Condition; Financial S | Agreement | View |
| 2025-08-06 | Departure/Election of Directors; Appointment of Officers; Financial Statements and Exhibits | View | |
| 2025-06-05 | Departure/Election of Directors; Appointment of Officers; Submission of Matters to a Vote of Securit | View | |
| 2025-05-15 | Amendments to Articles of Incorporation or Bylaws; Financial Statements and Exhibits | View | |
| 2025-05-08 | Results of Operations and Financial Condition; Financial Statements and Exhibits | View | |
| 2025-03-17 | Entry into Material Definitive Agreement; Regulation FD Disclosure; Financial Statements and Exhibit | Agreement | View |
| 2025-02-13 | Entry into Material Definitive Agreement; Results of Operations and Financial Condition; Financial S | Agreement | View |
| 2025-01-07 | Results of Operations and Financial Condition; Financial Statements and Exhibits | View |
Data extracted from SEC EDGAR 8-K filings using NLP. Relationships are as disclosed in filing text.
Covers 2021–2026. View on SEC EDGAR